[{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OTOF-GT","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OTOF-GT","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OTOF-GT","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"OTOF-GT","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Sensorion \/ Redmile Group","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Redmile Group"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OTOF-GT","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTOF-GT","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OTOF-GT","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OTOF-GT","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series D Financing","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ OrbiMed Advisors","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Otonomy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"OTO-413","moa":"BDNF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Otonomy \/ Inapplicable"},{"orgOrder":0,"company":"Otonomy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"OTO-413","moa":"BDNF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Otonomy \/ Inapplicable"},{"orgOrder":0,"company":"Otonomy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"OTO-413","moa":"BDNF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Otonomy \/ Inapplicable"},{"orgOrder":0,"company":"Otonomy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"OTO-413","moa":"BDNF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Otonomy \/ Inapplicable"},{"orgOrder":0,"company":"Pipeline Therapeutics","sponsor":"Franklin Templeton","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series C Financing","leadProduct":"PIPE-505","moa":"Gamma-secretase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Pipeline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Pipeline Therapeutics \/ Franklin Templeton","highestDevelopmentStatusID":"7","companyTruncated":"Pipeline Therapeutics \/ Franklin Templeton"},{"orgOrder":0,"company":"Pipeline Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PIPE-505","moa":"Gamma-secretase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Pipeline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Pipeline Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Pipeline Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"OTOF-GT","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
